Homocysteine: what drives it up, what brings it down

Homocysteine is one of the few lab markers that tells you something about how well your methylation cycle is actually running — right now, today, in your body. It’s cheap to measure, sensitive to diet and genetics, and responsive to targeted nutrient support. And it’s associated with meaningful downstream outcomes: cardiovascular risk, cognitive function, fertility, and pregnancy health.¹

Here’s what drives homocysteine up, what brings it back down, and how to interpret your number.

What homocysteine is and why the body tightly controls it

Homocysteine is a sulfur-containing amino acid — an intermediate, not a destination. It’s produced constantly when your body methylates compounds and the universal methyl donor (SAM-e) hands off its methyl group. The leftover molecule, S-adenosylhomocysteine, is rapidly broken down to homocysteine.

From there, your body has two main ways to clear it:

1. Remethylation — homocysteine gets recycled back into methionine. This requires 5-MTHF (active folate) as the methyl source and methylcobalamin (active B12) as the carrier enzyme cofactor.² Betaine (TMG) offers a secondary remethylation route in the liver.
2. Transsulfuration — homocysteine is routed toward cysteine and eventually glutathione via the enzyme cystathionine β-synthase, which is strictly dependent on B6 in its active form (P5P).²

Both exit ramps work in parallel. If either one stalls, homocysteine backs up and blood levels rise.

What “elevated” actually means

General reference ranges:

• Optimal: <7 μmol/L
• Normal (most labs): 5–15 μmol/L
• Mildly elevated: 15–30 μmol/L
• Moderately elevated: 30–100 μmol/L
• Severely elevated: > 100 μmol/L (usually reflects severe genetic enzyme deficiency)

Most “high” results in a functional medicine context sit in the 10–20 range — enough to signal the methylation cycle is working harder than it should, but not enough to trigger the kind of severe clinical picture seen in genetic enzyme disease.

Large cohort studies, including analyses from the Framingham Heart Study, have consistently linked elevated homocysteine to cardiovascular and cognitive outcomes at the population level, though individual risk depends on many factors.¹

What drives homocysteine up

Homocysteine goes up when the pathways that clear it slow down. The usual suspects:

Nutrient insufficiency. Low folate, B12, or B6 — any one of the three can raise homocysteine.³ Folic-acid-fortified foods don’t always translate to adequate active folate in people with impaired conversion (see our 5-MTHF vs folic acid primer).

MTHFR variants. The C677T polymorphism, present in ~40% of Americans, reduces MTHFR enzyme activity 30–70% depending on copy number.⁴ Homozygotes (677TT) consistently show higher average homocysteine than non-carriers — particularly when folate status is suboptimal.

Other methylation-pathway genetic variants. MTRR, MTR, CBS, and BHMT variants all affect remethylation or transsulfuration capacity.

Inadequate B12 absorption. Common in older adults (loss of stomach acid), long-term PPI or metformin users, vegans without supplementation, and people with pernicious anemia.

Hypothyroidism. Underactive thyroid reliably raises homocysteine.

Kidney function decline. Homocysteine is cleared in part through the kidneys; impaired function raises levels.

Lifestyle factors. Smoking, heavy alcohol use, high coffee intake, and a sedentary lifestyle all correlate with higher homocysteine.

Certain medications. Methotrexate, some anticonvulsants, nitrous oxide anesthesia, and fibrates can raise levels by interfering with folate or B12 metabolism.

What brings homocysteine down

The good news is that for most people, elevated homocysteine is highly responsive to targeted intervention. The core stack:

Active folate (L-5-MTHF). The methyl source for remethylation. In controlled trials, bioactive 5-MTHF raised red blood cell folate more effectively than folic acid — especially in people with MTHFR variants.⁵ Replace folic acid with L-5-MTHF (and/or folinic acid) if you have a confirmed variant.

Methylcobalamin (active B12). Methionine synthase — the enzyme that remethylates homocysteine — requires methyl-B12 as its cofactor. Oral B12 works for most; sublingual or injection may be needed for absorption issues.

P5P (active B6). Opens the transsulfuration exit ramp. Low plasma P5P is associated with elevated homocysteine.¹ See our piece on why P5P beats pyridoxine HCl for the full story.

Riboflavin (B2). The cofactor the MTHFR enzyme itself depends on. Some C677T homozygotes show particularly strong homocysteine reductions when B2 is added.

Betaine (TMG). Offers an alternate remethylation pathway that doesn’t require folate. Useful for patients who can’t tolerate methyl donors directly.

Lifestyle levers. Cutting smoking, moderating alcohol and coffee, and improving sleep all reduce homocysteine over time. Exercise alone has modest but consistent effects.

Large randomized trials of B-vitamin supplementation reliably lower homocysteine, though whether that translates to reduced hard cardiovascular endpoints has been inconsistent across studies.⁶ The clinical consensus: lowering elevated homocysteine is a reasonable target, especially when combined with broader metabolic and cardiovascular support.

Q: My homocysteine is 11. Is that actually high?

It’s in the “normal” range on most lab reports, but in functional medicine it’s often considered suboptimal — particularly if you have MTHFR variants, methylation symptoms, cardiovascular family history, or you’re planning pregnancy. Many practitioners target under 8 μmol/L. The right answer depends on your full picture: genetics, other labs, symptoms, and goals. Discuss the number — and any supplementation strategy — with a practitioner who can contextualize it for you.

How to test it

Fasting plasma homocysteine is a routine lab most practitioners can order. For a meaningful picture, most functional medicine providers run it alongside:

• Serum folate and RBC folate
• Serum B12 (and ideally methylmalonic acid, a more sensitive marker of functional B12 status)
• Plasma P5P
• TSH, free T3, free T4
• Comprehensive metabolic panel (for kidney and liver function)

If you want a deeper genetic picture — MTHFR plus other methylation-pathway variants — a comprehensive nutrigenomic panel like GenePro+ can surface the full dataset in one run. See also our primer on testing for MTHFR.

Putting it together

For the majority of people with elevated homocysteine, the fix isn’t exotic — it’s adequate active B-vitamins delivered in forms the body can use. Methylation Complete™ provides the three bioactive B’s (methylcobalamin, P5P, 5-MTHF) in a sublingual daily dose. For patients with confirmed MTHFR variants who need higher clinical folate support specifically, Methyl Folate Plus™ adds L-5-MTHF and folinic acid with B2 and B3 cofactors.

The short version

• Homocysteine is a sulfur amino acid produced by methylation and cleared by remethylation (folate + B12) or transsulfuration (B6 as P5P).
• Levels rise with low B-vitamins, MTHFR and related variants, hypothyroidism, kidney issues, certain medications, and lifestyle factors.
• Active forms — L-5-MTHF, methylcobalamin, P5P, plus riboflavin — reliably lower homocysteine in responsive patients.
• Target ranges and clinical meaning depend on your full picture; discuss with a practitioner before starting high-dose protocols.
• Retest 8–12 weeks after starting any new supplementation protocol to confirm response.

---

This article is educational and does not constitute medical advice. Homocysteine interpretation and supplementation protocols should be individualized and reviewed with a qualified healthcare provider, especially during pregnancy or if you take prescription medications.

References

Footnotes

1. Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr. 2006;136(6 Suppl):1726S–1730S. PMID: 16702347 ↩ ↩² ↩³

2. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217–246. PMID: 10448523 ↩ ↩²

3. Selhub J. Public health significance of elevated homocysteine. Food Nutr Bull. 2008;29(2 Suppl):S116–S125. PMID: 18709886 ↩

4. Frosst P et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111–113. PMID: 7647779 ↩

5. Prinz-Langenohl R et al. [6S]-5-methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild-type 677C→T polymorphism. Br J Pharmacol. 2009;158(8):2014–2021. PMID: 19917061 ↩

6. Toole JF et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565–575. PMID: 14762035 ↩